2023. Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program. SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s291. DOI:https://doi.org/10.25251/skin.7.supp.291.